Unknown

Dataset Information

0

Relugolix in Clinical Practice: The Best Route for All?


ABSTRACT: Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.

SUBMITTER: Cordes LM 

PROVIDER: S-EPMC10400131 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Relugolix in Clinical Practice: The Best Route for All?

Cordes Lisa M LM   Karzai Fatima F   Figg William D WD   Madan Ravi A RA  

The oncologist 20230801 8


Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and pe  ...[more]

Similar Datasets

| S-EPMC3359956 | biostudies-literature
| S-EPMC5802310 | biostudies-literature
| S-EPMC10417884 | biostudies-literature
| S-EPMC6037306 | biostudies-other
| S-EPMC9652828 | biostudies-literature
| S-EPMC4777975 | biostudies-literature
| S-EPMC8826142 | biostudies-literature
| S-EPMC11483803 | biostudies-literature
| S-EPMC7014729 | biostudies-literature
| S-EPMC9007443 | biostudies-literature